Table 3.
Diabetic retinopathy outcomes at Month 12 (M12) and Month 24 (M24) for the treatment-naïve and non-treatment-naïve cohort.
| Treatment-naïve | Non-treatment-naïve | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| M12 (N = 388) | M24 (N = 326) | M12 (N = 169) | M24 (N = 135) | ||||||
| BL n (%) | M12 n (%) | BL n (%) | M24 n (%) | BL n (%) | M12 n (%) | BL n (%) | M24 n (%) | ||
| English | R0 | 3 (1.2) | - | 3 (1.2) | 4 (1.7) | 1 (0.9) | 2 (1.9) | 1 (0.9) | 3 (2.8) |
| R1 | 94 (38.7) | 98 (40.3) | 94 (39.0) | 95 (39.4) | 37 (34.9) | 33 (31.1) | 37 (34.9) | 37 (34.9) | |
| R2 | 78 (32.1) | 61 (25.1) | 78 (32.4) | 50 (20.7) | 35 (33.0) | 30 (28.3) | 35 (33.0) | 27 (25.5) | |
| R3 | 41 (16.9) | 38 (15.6) | 41 (17.0) | 46 (19.1) | 18 (17.0) | 20 (18.9) | 18 (17.0) | 17 (16.0) | |
| Missing | 27 (11.1) | 46 (18.9) | 25 (10.4) | 46 (19.1) | 15 (14.2) | 21 (19.8) | 15 (14.2) | 22 (20.8) | |
| Scottish | R0 | - | 1 (2.2) | - | - | - | - | - | - |
| R1 | 21 (45.7) | 26 (56.5) | 21 (43.8) | 28 (58.3) | 4 (30.8) | 8 (61.5) | 4 (28.6) | 6 (42.9) | |
| R2 | 19 (41.3) | 10 (21.7) | 19 (39.6) | 10 (20.8) | 5 (38.5) | 2 (15.4) | 5 (35.7) | 3 (21.4) | |
| R3 | 3 (6.5) | 5 (10.9) | 3 (6.3) | 7 (14.6) | 4 (30.8) | 2 (15.4) | 4 (28.6) | 4 (28.6) | |
| R4 | - | 1 (2.2) | - | - | - | 1 (7.7) | - | - | |
| Missing | 3 (6.5) | 3 (6.5) | 5 (10.4) | 3 (6.3) | - | - | 1 (7.1) | 1 (7.1) | |
Outcomes are provided based on the English National Screening Committee (English) or Scottish Diabetic Retinopathy Grading Scheme (Scottish) classifications as appropriate.
English scale, R0 No visible retinopathy, R1 Background retinopathy, R2 Pre-proliferative retinopathy, R3 Proliferative retinopathy.
Scottish; R0 No visible retinopathy, R1 Mild retinopathy, R2 Observable retinopathy, R3 Referable retinopathy, R4 Proliferative retinopathy.